Arca
Skip to content
Tools
Tools

Optic neuritis

Drug research and approvals for optic neuritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 54 studies of optic neuritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 54
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 54 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

Phase 3 3

Phase 2 10

Phase 1 or earlier 3

How its trials ended

74 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 17 whose ending is known, 18% met their primary endpoint, 12% missed it and 71% stopped early.

  • Completed, result not reported2635%
  • Status unknown1723%
  • Ongoing1419%
  • Stopped: enrollment or feasibility79%
  • Met its primary endpoint34%
  • Stopped: other or unclear34%
  • Missed its primary endpoint23%
  • Stopped: sponsor or business decision23%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jun 10, 2026A randomized, double-masked, placebo-controlled study assessing the efficacy and safety of privosegtor (OCS-05) in patients with optic neuritis (ON)Privosegtor (OCS-05) / MethylprednisoloneOculis Operations SàrlPending
May 24, 2017A phase II trial of high-dose vitamin D induction in optic neuritis (vitadon 2)Vitamin DUniversity of CalgaryOngoing
Nov 18, 2015A multicenter, follow-up study to assess the long-term electrophysiologic and clinical outcomes in subjects previously enrolled in study 215on201BIIB033 (anti-lingo)BiogenOngoing

FDA orphan designations

Approved first, then open designations, newest first
Nov 9, 2021(R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy)…Treatment of Optic NeuritisTrethera CorporationDesignated
Sep 21, 2021MelatoninTreatment of optic neuritisWORPHMED SrlDesignated
Nov 17, 2014N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-iso…Treatment of optic neuritisOculis Operations SàrlDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.